Zoetis Announces the Completion of its Acquisition of Jurox, a Leading Provider of Livestock and Companion Animal Products
September 30 2022 - 7:00AM
Business Wire
- Increases Zoetis’ range of products, with potential for greater
global expansion
- Provides future growth opportunities, manufacturing capacity,
and insights into Australian animal health market
- Strengthens Zoetis’ anaesthetic portfolio with addition of
Alfaxan®, a leading anaesthetic for companion animals
Zoetis Inc. (NYSE: ZTS) today announced it has completed the
acquisition of Jurox, a privately held animal health company that
develops, manufactures and markets a wide range of veterinary
medicines for treating livestock and companion animals. Jurox’s
operations are based in Australia, with additional regional offices
in New Zealand, U.S., Canada and the UK. Financial terms of the
transaction, which was announced in August 2021, are not being
disclosed.
The acquisition of Jurox brings Zoetis a range of important
products primed for greater global expansion; a valuable animal
health portfolio, including Alfaxan®, a leading anaesthetic product
for companion animals; and high-quality local R&D and
manufacturing operations in Australia, Zoetis’ fourth largest
market based on revenue in 2021.
“We are grateful to the O’Brien family for entrusting the future
of this family-owned business to Zoetis,” said Zoetis CEO Kristin
Peck. “Jurox’s portfolio plays to the strengths of our core
business and will be a complementary fit with the solutions we
deliver to veterinary professionals, livestock producers and pet
owners around the world,” said Peck. “With Zoetis’ global sales and
regulatory expertise in more than 45 markets, we look forward to
expanding the impact and reach of the entire Jurox portfolio.”
Jurox develops and manufactures more than 150 products in areas
such as parasiticides, anti-infectives, anaesthesia, cardiology and
reproduction for animals.
About Zoetis As the world’s leading animal health
company, Zoetis is driven by a singular purpose: to nurture our
world and humankind by advancing care for animals. After 70 years
innovating ways to predict, prevent, detect, and treat animal
illness, Zoetis continues to stand by those raising and caring for
animals worldwide – from livestock farmers to veterinarians and pet
owners. The company’s leading portfolio and pipeline of medicines,
vaccines, diagnostics and technologies make a difference in over
100 countries. A Fortune 500 company, Zoetis generated revenue of
$7.8 billion in 2021 with approximately 12,100 employees. For more
information, visit www.zoetis.com.
About Jurox Founded in 1992, Jurox formulates,
manufactures and distributes companion and commercial animal health
products from its CGMP-compliant facility located in the Hunter
Valley region, New South Wales, Australia. Jurox products,
including a leading anaesthetic product Alfaxan, are currently
distributed Australia, the US and more than 20 other countries
around the world. For more information, visit www.jurox.com.au.
Forward-Looking Information This press release contains
forward-looking statements, which reflect the current views of
Zoetis with respect to: expectations regarding the performance of
acquired companies and our ability to integrate new businesses;
expectations regarding the financial impact of acquisitions;
business plans or prospects, future operating or financial
performance, future guidance, future operating models; R&D
costs, timing and likelihood of success; expectations regarding
products, product approvals or products under development; expected
timing of product launches; the impact of the coronavirus
(COVID-19) global pandemic and any recovery therefrom on our
business, supply chain, customers and employees; future use of
cash, dividend payments and share repurchases; tax rate and tax
regimes and any changes thereto; and other future events. These
statements are not guarantees of future performance or actions.
Forward-looking statements are subject to risks and uncertainties.
If one or more of these risks or uncertainties materialize, or if
management's underlying assumptions prove to be incorrect, actual
results may differ materially from those contemplated by a
forward-looking statement. Forward-looking statements speak only as
of the date on which they are made. Zoetis expressly disclaims any
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or otherwise.
A further list and description of risks, uncertainties and other
matters can be found in our Annual Report on Form 10-K for the
fiscal year ended December 31, 2021, including in the sections
thereof captioned “Forward-Looking Statements and Factors That May
Affect Future Results” and “Item 1A. Risk Factors,” in our
Quarterly Reports on Form 10-Q and in our Current Reports on Form
8-K. Such risks and uncertainties may be amplified by the COVID-19
global pandemic and its potential impact on the global economy and
our business. These filings and subsequent filings are available
online at www.sec.gov, www.zoetis.com or on request from
Zoetis.
ZTS-COR ZTS-IR
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220929005878/en/
Media: Bill Price 1-973-443-2742
(o) William.price@zoetis.com
Ben Reay +61 477 710 681 Ben.Reay@zoetis.com
Investors (if
applicable): Steve Frank 1-973-822-7141 (o)
Steve.frank@zoetis.com
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Zoetis (NYSE:ZTS)
Historical Stock Chart
From Jul 2023 to Jul 2024